Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-term Survival of Unresectable Hepatocellular Carcinoma Patients Receiving Lenvatinib-based Therapy: A Retrospective, Multicenter Propensity Score Matching Study

NCT07298538 is registered in ClinicalTrials.gov with Tianjin Medical University Cancer Institute and Hospital as lead sponsor.

NCT NCT07298538
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07298538 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long-term Survival of Unresectable Hepatocellular Carcinoma Patients Receiving Lenvatinib-based Therapy: A Retrospective, Multicenter Propensity Score Matching Study
Lead sponsor
Tianjin Medical University Cancer Institute and Hospital
Phase
Observational
Overall status
Active, not recruiting
Start date
January 1, 2019
Completion date
December 31, 2027
Enrollment
800 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

unresectable hepatocellular carcinoma